Sinografin | 3521-84-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Sinografin
• 英文别名: 3-[[6-(3-carboxylato-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoate;methyl-[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]azanium
• CAS: 3521-84-4
• 化学式: C34H48I6N4O16
• 分子量: 1530.2
• InChiKey: DGIAUNUPXILTJW-VRWDCWMNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.13
• 重原子数：
  60
• 可旋转键数：
  21
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  359
• 氢给体数：
  16
• 氢受体数：
  18

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：静脉注射碘对比剂在乳汁中排泄不良，且口服吸收不良，因此它们不太可能进入婴儿的血液循环或对母乳喂养的婴儿产生任何不良影响。一些专业组织制定的指南指出，在哺乳母亲接受含碘对比剂后，不需要中断哺乳。然而，由于在哺乳期间使用碘碘酰胺的经验尚未发表，其他药物可能更为首选，特别是在哺乳新生儿或早产儿时。 ◉ 对母乳喂养婴儿的影响：截至修订日期，没有找到相关的已发布信息。 ◉ 对泌乳和乳汁的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:Intravenous iodinated contrast media are poorly excreted into breastmilk and poorly absorbed orally so they are not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. Guidelines developed by several professional organizations state that breastfeeding need not be disrupted after a nursing mother receives an iodine-containing contrast medium. However, because there is no published experience with iodipamide during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

制备方法与用途

类别：有毒物品

毒性分级：中毒

急性毒性：

• 静脉注射大鼠 LD50：5000 毫克/公斤
• 静脉注射小鼠 LD50：3195 毫克/公斤

可燃性危险特性：可燃；燃烧时产生有毒氮氧化物和碘化物烟雾

储运特性：通风、低温、干燥

灭火剂：干粉、泡沫、沙土、二氧化碳、雾状水

文献信息

• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。
• Contrast agents
  申请人：Ostensen Jonny

  公开号：US20050118104A1

  公开（公告）日：2005-06-02

  Ultrasonic visualisation of a suject, particularly of perfusion in the myocardium and other tissues, is performed using novel gas-containing contrast agent preparations which promote controllable and temporary growth of the gas phase in vivo following administration and can therefore act as deposited perfusion tracers. The preparations include a coadministerable composition comprising a diffusible component capable of inward diffusion into the dispersed gas phase to promote temporary growth thereof. In cardiac perfusion imaging the preparations may advantageously be coadministered with vasodilator drugs such as adenosine in order to enhance the differences in return signal intensity from normal and hypoperfused myocardial tissue respectively.

  使用新型气体含量对比剂制剂进行超声可视化检查，特别是对心肌和其他组织的灌注进行检查，这些制剂可以促进在体内可控和暂时的气相生长，并因此可以作为沉积的灌注示踪剂。这些制剂包括一种可共同给予的组合物，其中包括一种可向分散的气相内部扩散的可扩散成分，以促进其暂时生长。在心脏灌注成像中，这些制剂可以有利地与血管扩张药物（如腺苷）共同给予，以增强正常和低灌注心肌组织的回波信号强度差异。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF
  申请人：Rogers Robin D.

  公开号：US20120046244A1

  公开（公告）日：2012-02-23

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are ‘solvated,’ for example, ‘hydrated’ and their uses.

  本文揭示了包括活性药物、生物和营养化合物的离子液体组成，以及使用方法。进一步揭示了液态离子对或其溶液的物质组成和使用方法；包括“溶剂化”的离子液体组成，例如“水化”的离子液体组成及其用途。